The protective effect of cannabinoid type 2 receptor activation on renal ischemia–reperfusion injury

Autor: Suat Tekin, Emin Kaymak, Murat Cakir, Züleyha Doğanyiğit, Pınar Çakan
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Interleukin-1beta
Clinical Biochemistry
Kidney
Blood Urea Nitrogen
Rats
Sprague-Dawley
Receptor
Cannabinoid
CB2
chemistry.chemical_compound
0302 clinical medicine
Cannabinoid receptor type 2
biology
Caspase 3
Interleukin-18
NF-kappa B
General Medicine
Lipocalins
Interleukin-10
medicine.anatomical_structure
Creatinine
Reperfusion Injury
030220 oncology & carcinogenesis
medicine.symptom
medicine.medical_specialty
Ischemia
Inflammation
Protective Agents
03 medical and health sciences
Lipocalin-2
Proto-Oncogene Proteins
Internal medicine
medicine
Animals
Cystatin C
Molecular Biology
Renal ischemia
Cannabinoids
Interleukin-6
Tumor Necrosis Factor-alpha
business.industry
Cell Biology
medicine.disease
030104 developmental biology
Endocrinology
chemistry
JWH-133
biology.protein
business
Acute-Phase Proteins
Zdroj: Molecular and Cellular Biochemistry. 462:123-132
ISSN: 1573-4919
0300-8177
DOI: 10.1007/s11010-019-03616-6
Popis: Kidney ischemia reperfusion (IR) injury is an important health problem resulting in acute renal failure. After IR, the inflammatory and apoptotic process is triggered. The relation of Cannabinoid type 2 (CB2) receptor with inflammatory and apoptotic process has been determined. The CB2 receptor has been shown to be localized in glomeruli and tubules in human and rat kidney. Activation of CB2 receptor with JWH-133 has been shown to reduce apoptosis and inflammation. In this study, it was investigated whether CB2 activation with selective CB2 receptor agonist JWH-133 was protective against renal IR injury. Male Sprague-Dawley rats were divided into 5 groups (n = 45). Bilateral ischemia was treated to the IR group rat's kidneys for 45 min and then reperfusion was performed for 24 h. Three different doses of JWH-133 (0.2, 1 and 5 mg/kg) were administered to the treatment groups at the onset of ischemia. The JWH-133 application at three different doses decreased the glomerular and tubular damage. Additionally, in the renal tissue, nuclear factor-κB, tumour necrosis factor alpha, interleukin-1beta, and caspase-3 levels decreased immunohistochemically. Similarly, JWH-133 application decreased the serum tumour necrosis factor alpha, blood urea nitrogen, creatinine, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, Cystatin C, interleukin-18, interleukin-1beta, interleukin-6, and interleukin-10 levels. We found that JWH-133 and CB2 receptor activation had a curative effect against kidney IR damage. JWH-133 may be a new therapeutic agent in preventing kidney IR damage.
Databáze: OpenAIRE
Externí odkaz: